Skip to main content
logo
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
18.98
-0.03 (-0.16%)
Apr 29, 2026, 10:57 AM EDT - Market open

Monte Rosa Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Cap
1,5191,028427283375950
Market Cap Growth
485.08%140.76%50.68%-24.53%-60.50%-
Enterprise Value
1,183685.4293.7193.76156.4604.19
Last Close Price
18.9815.686.945.657.6120.42
PE Ratio
--34.09-7.08-2.15-3.31-6.90
PS Ratio
12.308.315.64---
PB Ratio
5.354.411.911.581.382.73
P/TBV Ratio
6.745.592.301.621.321.47
P/FCF Ratio
--37.3711.23-4.51-3.56-13.75
P/OCF Ratio
--45.0810.16-6.47-4.06-16.01
EV/Sales Ratio
9.575.541.24---
EV/EBITDA Ratio
--14.95-1.28-0.68-1.44-8.54
EV/EBIT Ratio
--12.64-1.16-0.65-1.39-8.29
EV/FCF Ratio
--24.932.47-1.49-1.48-8.74
Debt / Equity Ratio
0.150.150.170.240.160
Debt / EBITDA Ratio
-0.85-0.85-0.58-0.34-0.43-
Debt / FCF Ratio
-1.42-1.421.12-0.73-0.45-
Net Debt / Equity Ratio
-1.45-1.45-1.48-1.04-0.79-1.00
Net Debt / EBITDA Ratio
7.377.374.511.361.994.89
Net Debt / FCF Ratio
12.2912.29-8.672.972.055.01
Asset Turnover
0.280.280.20000
Quick Ratio
6.056.052.375.0010.5820.80
Current Ratio
6.126.122.405.0710.7920.96
Return on Equity (ROE)
-16.94%-16.94%-36.15%-60.07%-35.06%-40.35%
Return on Assets (ROA)
-11.88%-11.88%-22.65%-44.47%-31.71%-35.06%
Return on Invested Capital (ROIC)
-146.63%-146.63%-220.77%-279.75%-370.04%-8554.23%
Return on Capital Employed (ROCE)
-16.27%-16.27%-30.10%-49.94%-33.72%-39.42%
Earnings Yield
-2.54%-2.93%-14.12%-46.55%-30.22%-14.50%
FCF Yield
-1.81%-2.68%8.90%-22.18%-28.07%-7.27%
Buyback Yield / Dilution
-12.39%-12.40%-43.80%-8.83%-88.91%-1548.09%
Total Shareholder Return
-12.39%-12.40%-43.80%-8.83%-88.91%-1548.09%
Updated Mar 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q